-
Turning Rare Disease Research into Everyday Hope
In the early 1990s, Dr. Emil Kakkis developed a groundbreaking treatment for mucopolysaccharidosis type I (MPS I), a rare genetic lysosomal storage disorder that was once…
Donor -
In Memoriam: Dr. Harriet S. Kaplan (1929–2026)
Dr. Harriet Smith Kaplan, a pioneering psychiatrist, devoted physician, beloved mentor, and former investigator at The Lundquist Institute (TLI), passed away peacefully on January 3, 2026, at the age of 96.…
Donor -
A Life of Purpose: Honoring Ginny Bleier’s Legacy at The Lundquist Institute
Virginia “Ginny” Bleier lived a life defined by curiosity, compassion, and adventure. A dedicated nurse, lifelong learner, and passionate traveler, Ginny’s warmth and generosity touched everyone…
Donor -
From Personal Passion to Strategic Impact: The Lundquist Institute’s Philanthropic Champions
As a child, Melanie Lundquist and her family had a deeply personal connection to Tay-Sachs disease, a rare genetic condition that destroys nerve cells in the…
Donor -
Charting the Future of TLI with CEO Joe W. Ramos, PhD
Join us on Wednesday, May 7 as we celebrate a new chapter for The Lundquist Institute under the leadership of CEO Joe W. Ramos, PhD.
Donor -
Lundquist Institute Investigator Dr. Matt Budoff Receives $1 Million Gift from the Stanley W. Ekstrom Foundation
The Gift Will be Used to Study the Effects of the Anti-Inflammatory Colchicine in People with Coronary Artery Disease
Donor -
The Lundquist Institute Receives $1.5 Million Gift from Farima and Joseph Czyzyk to Make Life-Saving Technology Accessible to the Public
The Diagnostic and Wellness Center will be Renamed the Farima Czyzyk Center for Cardiac Research and Wellness
Donor -
The Lundquist Institute Releases Its 2020 Year in Review
In a Year Dominated by the Global COVID Pandemic, The Institute Kept Moving Forward
Community, Donor, Education, Research -
The Lundquist Institute Accepts a $1.75 Million Anonymous Donation to Improve the Quality of Dying
Psilocybin clinical project will investigate efficacy and safety of a psychedelic compound for those under severe psychological distress from terminal illness
Donor